Fidelity
Home > Boards > US OTC > Biotechs >

Nuvilex, Inc. (NVLX)

NVLX RSS Feed
Add NVLX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Alydyr, anarmyofme, thnikkamax, lastcall59, TheBestInvest
Search This Board:
Last Post: 4/18/2014 7:48:14 PM - Followers: 443 - Board type: Free - Posts Today: 0

                                      WORK IN PROGRESS                                          


Nuvilex      


                                            

Nuvilex Company Address
   Nuvilex, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851
   email: info@nuvilex.com


Shares Outstanding:
593,411,348 a/o Dec 13, 2013

Authorized Shares:
N/A

Float:
N/A
For more updated information please visit: 
http://www.otcmarkets.com/stock/NVLX/company-info



Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations
Marlin Molinaro
Marmel Communications, LLC
Phone: (702) 434-8692
email: mmolinarofc@aol.com


                                               

All News Releases: 
http://www.nuvilex.com/latest-news


Nuvilex is a biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box(TM). This unique technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. The Company's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box(TM) technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide.

Nuvilex has acquired worldwide exclusive rights to the cellulose-based live cell-encapsulation technology, also known as Cell-in-a-Box™, and described above, from SG Austria Pte. Ltd. for the development of treatments for any and all types of cancer. The rights to use the cancer drug-activating cells that will be part of Nuvilex’s treatment for advanced pancreatic cancer (see Pancreatic Cancer section of this website) were also acquired. The acquisition of rights to use the Cell-in-a-Box™ technology for the development of treatments for insulin-dependent diabetes has recently been completed.

Austria Nova Demonstration Video


The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool.

 

Medical Marijuana Sciences

 
                                                                                                                                   

                                                       



 


Management Team:
 

Kenneth L. Waggoner, Chief Executive Officer and President:

Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.

Dr. Robert F. Ryan, Chief Scientific Officer:

 

Dr. Robert F. Ryan was named Chief Scientific Officer. Dr. Ryan has broad scientific experience in biochemistry, cell and molecular biology, human genetics, novel therapies, and basic and clinical cancer research, having received his Masters in Biochemistry, Cell and Molecular Biology at The Medical College of Georgia, studying sickle cell anemia. He received his Ph.D. in Molecular Genetics at Thomas Jefferson University characterizing DNA and RNA binding properties of zinc finger proteins. Through his extensive training, his experiences extend across the fields of aging, hemoglobinopathies, gene expression, human diseases, DNA, RNA, proteins and their interactions, stem cell research and applications, oncology, clinical protocols and therapies.

Professionally, Dr. Ryan has become a pioneer in the field of emerging biotechnology, specializing in assisting small companies with insight and bringing products to market through the rigorous FDA approval process. Since 2002, Dr. Ryan served as the Chief Executive Officer of RFR Consulting where he focused on helping businesses in the biotech industry through providing information, grant writing, business management, scientific guidance, FDA regulatory advice, advising investors, and investment acquisition opportunities. With 25 years experience including excellent training at the Wistar Institute, NIH, and NCI, he has participated in basic and clinical investigations and has published and edited research articles in several peer-reviewed journals.

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:

 

Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Patricia Gruden – Chief Financial Officer and Chairman of the Board:

 

Patricia Gruden is the Chief Financial Officer of the Company and Chairman of the Board.  Ms. Gruden has made a substantial impact on the Company since its inception.  In 1995, Ms. Gruden became cofounder of the company that later became Nuvilex, Inc.  The original company was initiated to develop a software program through accurately tracking produce from the field to the table, including the challenges of shipping, temperature variation and maintenance and everything else concerning the distribution of produce worldwide.  In addition, the Company developed an ozone cleaning system to kill bacteria on produce without leaving harmful residue on the product and without harming the environment. 

Over the years Ms. Gruden has carried out almost every job in the Company, including developer, shipper, President, CEO, Chairman of the Board, CFO and many others.  As a result, she has been intricately aware of all aspects of the Company and its products.  After a brief semi-retirement in 2009-10, Ms. Gruden returned to make arrangements for necessary funding and to assist the Company in changing from a nutraceutical company to a biotechnology company.  Her training has not only included real world experiences of running more than one company, Ms. Gruden embraces every business opportunity with excitement, clarity and focus.  Ms. Gruden has a long history of owning her own businesses and doing so successfully. Additionally, a strong community presence allowed her to act as President of the local Chamber of Commerce and Arizona Small Business Association.  She has also been active in Habitat for Humanity, shelters for abused women and children and the Ronald McDonald House.

 

Stock Chart http://www.otcmarkets.com/stock/NVLX/chart
Company Info http://www.otcmarkets.com/stock/NVLX/company-info
Recent News http://www.otcmarkets.com/stock/NVLX/news
Financials http://www.otcmarkets.com/stock/NVLX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/NVLX/filings
Short Sales http://www.otcmarkets.com/stock/NVLX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/NVLX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/NVLX/research
Summary http://finance.yahoo.com/q?s=NVLX
Historical Prices http://finance.yahoo.com/q/hp?s=NVLX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=NVLX
Basic Chart http://finance.yahoo.com/q/bc?s=NVLX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=NVLX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=NVLX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=NVLX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=NVLX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=NVLX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=NVLX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=NVLX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=NVLX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=NVLX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=NVLX
Balance Sheet http://finance.yahoo.com/q/bs?s=NVLX
Cash Flow http://finance.yahoo.com/q/cf?s=NVLX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/NVLX
Market Watch http://www.marketwatch.com/investing/stock/NVLX
Bloomberg http://www.bloomberg.com/quote/NVLX:US
Morningstar http://quotes.morningstar.com/stock/s?t=NVLX
Bussinessweek http://investing.businessweek.com/research/st...icker=NVLX
Barchart http://www.barchart.com/quotes/stocks/NVLX
OTC Short Report http://otcshortreport.com/index.php?index=NVLX
Investopedia http://www.investopedia.com/markets/stocks/NVLX/?wa=0


                                 

PostSubject
#19505  Sticky Note I did research on patents. 20 years for Otsy 04/09/14 02:37:13 PM
#19044  Sticky Note ATTENTION: Nuvilex, Inc. Releases Industry-Changing News Today!! bulldurham 04/02/14 01:56:03 PM
#18941  Sticky Note Nuvilex Selects Translational Drug Development (TD2) to Advance bulldurham 04/01/14 09:21:59 AM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#19890  Restored too many good things and people involved....... YellowKing 04/18/14 07:48:14 PM
#19889   That video basically says it all. Ifosfamide SeeingGreen420 04/18/14 06:05:08 PM
#19888   Nice promo video: http://m.youtube.com/watch?v=3JuvVKZHk7E alsoconcerned 04/18/14 05:29:33 PM
#19887   I also intend to purchase more NVLX next Otsy 04/18/14 01:30:48 PM
#19886   walterm32 IPO question. here are links that will Otsy 04/18/14 01:24:49 PM
#19885   Always enjoy your posts and thanks for sharing Peacefulwendy 04/18/14 01:15:05 PM
#19884   That was a great read, Thanks. rayla1961 04/18/14 12:09:44 PM
#19883   My two cents for what it is worth. Otsy 04/18/14 11:11:47 AM
#19882   I think that is a great strategy. I'm Otsy 04/18/14 09:11:49 AM
#19881   I hear you, but just not sure of TheB.E.T 04/18/14 07:45:34 AM
#19878   Good thought. dustfinder 04/17/14 10:49:09 PM
#19876   Wendy...this is in the very best hands...Crabtree was efood125 04/17/14 10:35:26 PM
#19874   Is this really news? Seems like hype with TheB.E.T 04/17/14 07:00:47 PM
#19873   Actually, I am pretty impressed with this technology Peacefulwendy 04/17/14 06:55:55 PM
#19872   Of course there's others. This technology has been brando5 04/17/14 06:44:53 PM
#19871   I hate to say it but if they moneyhungary 04/17/14 05:44:49 PM
#19870   Nice news today...... YellowKing 04/17/14 05:21:57 PM
#19869   Whew! You know $NVLX needed that today. TrendVestor 04/17/14 05:13:59 PM
#19868  Restored Great post as always bull, thank you. TheBestInvest 04/17/14 04:48:23 PM
#19867   Awesome, BULL! Love your commentary, so apropos! Peacefulwendy 04/17/14 04:40:27 PM
#19865   Thanks for highlighting a key player and his Peacefulwendy 04/17/14 04:32:51 PM
#19864   Closed @ .349. What is your take Peacefulwendy 04/17/14 04:29:47 PM
#19862   THANKS FOR POINTING THAT OUT ALYDYR Emmmci 04/17/14 03:36:26 PM
#19861   Good day for NVLX. Glad I bought back walterm32 04/17/14 03:08:59 PM
#19860   You have a way with words. I believe Otsy 04/17/14 02:54:56 PM
#19859   Alydyr, I consider that good news. All PR's Otsy 04/17/14 02:49:40 PM
#19858   Getting Accelerated Approval bulldurham 04/17/14 02:40:47 PM
#19856   Bull, In addition, Gilead's new drug, Sovaldi has Otsy 04/17/14 02:39:15 PM
#19855  Restored STOCK PROMOTER DISCLAIMER from today's NVLX PR. Alydyr 04/17/14 02:29:16 PM
#19854   Nuvilex rides the waves like the other bio's.....so bulldurham 04/17/14 02:09:26 PM
#19853   Von Hoff History with developing FDA approved drugs joe_techi 04/17/14 02:04:39 PM
#19852   No doubt. Shorts are gonna short. Long weekend walterm32 04/17/14 02:02:08 PM
#19851   What happens in 2 weeks? ada 04/17/14 01:46:18 PM
#19849   That would give them a huge edge with Peacefulwendy 04/17/14 01:34:52 PM
#19846   Lets slit the throats of all cancers an dustfinder 04/17/14 01:10:36 PM
#19845   My dd's are shared with close people, can Eltp 04/17/14 01:10:28 PM
#19844   The answer to your question is HFT's. If novyarbat 04/17/14 01:06:57 PM
#19840   Who are you to say true shorter or Eltp 04/17/14 12:53:20 PM
#19838   Any thoughts on 2 weeks from now ada? dustfinder 04/17/14 12:47:53 PM
#19837   I bought and sold, I've a hankrin to dustfinder 04/17/14 12:44:44 PM
#19836   Very nice turn around. Holding right around the ada 04/17/14 12:43:39 PM
#19835  Restored PUMP-N-DUMP in play NOW here at NVLX. Alydyr 04/17/14 12:39:29 PM
#19834   Well said Eltp, DO YOUR DD PEOPLE!!! Keep SeeingGreen420 04/17/14 12:35:36 PM
#19833   NVLX is heating up!!!!!!! GreenShootz 04/17/14 12:32:38 PM
#19831   ada boy. dustfinder 04/17/14 12:28:44 PM
#19830   Good analogy, you could win the lottery tomorrow. joe_techi 04/17/14 12:26:42 PM
#19828   Mods, please post the below ihub message number Peacefulwendy 04/17/14 12:22:55 PM
#19827   I couldn't understand why today's news caused the senderos 04/17/14 12:17:10 PM
#19826   It would be fair to say that everyone Traderintx 04/17/14 12:15:15 PM
#19825   This is my first bio but I have Peacefulwendy 04/17/14 12:13:45 PM
PostSubject